Literature DB >> 25750251

Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology.

Michael Marrone1, Richard L Schilsky2, Geoff Liu3, Muin J Khoury4, Andrew N Freedman5.   

Abstract

Within current oncology practice, several genomic applications are being used to inform treatment decisions with molecularly targeted therapies in breast, lung, colorectal, melanoma, and other cancers. This commentary introduces a conceptual framework connecting the full spectrum of biomedical research disciplines, including fundamental laboratory research, clinical trials, and observational studies in the translation of genomic applications into clinical practice. The conceptual framework illustrates the contribution that well-designed observational epidemiologic studies provide to the successful translation of these applications, and characterizes the role observational epidemiology plays in driving the dynamic and iterative bench-to-bedside, and bedside-to-bench translation continuum. We also discuss how the principles of this conceptual model, emphasizing integration of multidisciplinary research, can be applied to the evolving paradigm in "precision oncology" focusing on multiplex tumor sequencing, and we identify opportunities for observational studies to contribute to the successful and efficient translation of this paradigm.Cancer Epidemiol Biomarkers Prev; 24(3); 484-9. ©2015 AACR. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 25750251      PMCID: PMC4679177          DOI: 10.1158/1055-9965.EPI-14-1086

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

Review 1.  Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine.

Authors:  Felix W Frueh
Journal:  Pharmacogenomics       Date:  2009-07       Impact factor: 2.533

2.  Turning the Titanic.

Authors:  Elias A Zerhouni
Journal:  Sci Transl Med       Date:  2014-01-29       Impact factor: 17.956

3.  Stage- and tissue-specific expression of the neu oncogene in rat development.

Authors:  Y Kokai; J A Cohen; J A Drebin; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

6.  Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.

Authors:  L Lennard; C A Rees; J S Lilleyman; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

9.  Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ.

Authors:  Richard L Schilsky; Dina L Michels; Amy H Kearbey; Peter Paul Yu; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2014-06-09       Impact factor: 44.544

10.  L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.

Authors:  M M Nau; B J Brooks; J Battey; E Sausville; A F Gazdar; I R Kirsch; O W McBride; V Bertness; G F Hollis; J D Minna
Journal:  Nature       Date:  1985 Nov 7-13       Impact factor: 49.962

View more
  5 in total

1.  Precision Oncology Framework for Investigation of Exercise As Treatment for Cancer.

Authors:  Lee W Jones
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544

Review 2.  Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors.

Authors:  Rita K Schmutzler; Björn Schmitz-Luhn; Bettina Borisch; Peter Devilee; Diana Eccles; Per Hall; Judith Balmaña; Stefania Boccia; Peter Dabrock; Günter Emons; Wolfgang Gaissmaier; Jacek Gronwald; Stefanie Houwaart; Stefan Huster; Karin Kast; Alexander Katalinic; Sabine C Linn; Sowmiya Moorthie; Paul Pharoah; Kerstin Rhiem; Tade Spranger; Dominique Stoppa-Lyonnet; Johannes Jozef Marten van Delden; Marc van den Bulcke; Christiane Woopen
Journal:  Breast Care (Basel)       Date:  2021-08-12       Impact factor: 2.268

3.  Differences in Effectiveness and Use of Robotic Surgery in Patients Undergoing Minimally Invasive Colectomy.

Authors:  M Schootman; S Hendren; T Loux; K Ratnapradipa; J M Eberth; N O Davidson
Journal:  J Gastrointest Surg       Date:  2017-05-31       Impact factor: 3.452

4.  Differences in effectiveness and use of laparoscopic surgery in locally advanced colon cancer patients.

Authors:  M Schootman; Matthew Mutch; T Loux; J M Eberth; N O Davidson
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

Review 5.  Applications of RNA Indexes for Precision Oncology in Breast Cancer.

Authors:  Liming Ma; Zirui Liang; Hui Zhou; Lianghu Qu
Journal:  Genomics Proteomics Bioinformatics       Date:  2018-05-09       Impact factor: 7.691

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.